Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS – Get Rating) shares crossed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $1.08 and traded as low as $0.93. Pieris Pharmaceuticals shares last traded at $0.94, with a volume of 4,307,414 shares.
Wall Street Analyst Weigh In
Separately, StockNews.com upgraded Pieris Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, November 14th.
Pieris Pharmaceuticals Stock Performance
The firm has a market cap of $70.02 million, a P/E ratio of -2.00 and a beta of 1.08. The firm has a fifty day moving average of $1.08 and a 200-day moving average of $1.51.
Institutional Trading of Pieris Pharmaceuticals
Hedge funds have recently made changes to their positions in the stock. Tower Research Capital LLC TRC lifted its holdings in shares of Pieris Pharmaceuticals by 9,665.2% in the 3rd quarter. Tower Research Capital LLC TRC now owns 21,581 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 21,360 shares during the last quarter. Mackenzie Financial Corp bought a new stake in shares of Pieris Pharmaceuticals in the 2nd quarter worth approximately $26,000. Oppenheimer & Co. Inc. bought a new stake in shares of Pieris Pharmaceuticals in the 1st quarter worth approximately $32,000. Mirabella Financial Services LLP bought a new stake in shares of Pieris Pharmaceuticals in the 1st quarter worth approximately $39,000. Finally, Two Sigma Investments LP bought a new stake in Pieris Pharmaceuticals during the 3rd quarter valued at $43,000. Institutional investors own 50.17% of the company’s stock.
Pieris Pharmaceuticals Company Profile
Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids.
- Get a free copy of the StockNews.com research report on Pieris Pharmaceuticals (PIRS)
- After Nixing its 13% Dividend, Is Lumen Technologies Okay To Own?
- Cisco Systems Hopes Restructuring Cuts Costs to Drive Revenue
- The Sell-Side Caps Gains In Dick’s Sporting Goods
- Want to Get a 10% Dividend Yield, Look Here
- Stock-ing Stuffers: 3 Attractive Stocks Trading Around $10
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.